You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

69 items

Newly diagnosed cases of cervical carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Cervix
Biomarker: HPV
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Newly diagnosed cases of penile carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Penile
Biomarker: HPV
Testing Method:In Situ Hybridization (ISH)
Testing Site: Hamilton Health Sciences, Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Newly diagnosed cases of squamous cell carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Head and Neck
Biomarker: HPV
Testing Method:In Situ Hybridization (ISH)
Testing Site: Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, Sunnybrook Health Sciences Centre, University Health Network

Promoter Methylation testing should be performed for all MMR cases with abnormal MLH1 results*.

Funded Biomarker Disease Site: Adrenal Gland, Bladder/ Urothelial, Colorectal, Endometrium, Esophagus, Hepatobiliary, Ocular, Ovary, Pancreas, Skin, Small Bowel, Stomach
Biomarker: MLH1 Methylation
Testing Method:Methylation
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, Trillium Health Partners, University Health Network

Reflex testing for all newly diagnosed paragangliomas (to inform need for germline testing)

Funded Biomarker Disease Site: Multiple Disease Sites
Biomarker: SDHB
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Mount Sinai Hospital, Sunnybrook Health Sciences Centre, University Health Network, William Osler Health System

Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.

Funded Biomarker Disease Site: Ovary
Biomarker: p53, WT1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on all metastatic thyroid cancer, including sporadic medullary and radio-iodine refractory well differentiated thyroid cancer.

Funded Biomarker Disease Site: Thyroid
Biomarker: BRAF, HRAS, NRAS, NTRK3, PPARG, RET, KRAS
Testing Method:Panel
Testing Site: Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing on all newly diagnosed breast cancers.

Funded Biomarker Disease Site: Breast
Biomarker: HER2, ER, PR
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital

Reflex testing on all newly diagnosed breast cancers.

Funded Biomarker Disease Site: Breast
Biomarker: HER2
Testing Method:In Situ Hybridization (ISH)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital

Reflex testing on all newly diagnosed ductal carcinoma in situ (DCIS).

Funded Biomarker Disease Site: Breast
Biomarker: ER
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital

Reflex testing on cases of adult patients with persistent, recurrent, or metastatic cervical cancer when treatment is being considered

Funded Biomarker Disease Site: Cervix
Biomarker: PD-L1  (CPS ≥1)
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on newly diagnosed adult cases of Ependymoma (infratentorial).

Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: chrom 1q gain, chrom 6q loss
Testing Method:Fluoroscence In Situ Hybridization (FISH), Single Nucleotide Polymorphism (SNP) Array
Testing Site: Hospital for Sick Children (SickKids)

Pages